Appointment Expected to Support Initiatives to Improve Population Health Management and the Company’s Planned Listing Upgrade from OTCBQB to NASDAQ
Vinay Mehindru joins Retinalgenix Board of Directors
Vinay Mehindru, MD, MBA
PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies, Inc. Board of Directors.
Dr. Mehindru is a multi-talented top-level executive with over 25 years of healthcare experience. His leadership spans population health and financial performance management. He has led multiple physician performance enhancement strategies and built stakeholder alliances with clinical and financial integration. He is currently serving on the board of directors of Sanovas, Inc., SteriView™ Technologies, Inc., Intubation Science™, Inc, SinuGeniX™, Inc., OtoGeniX™ Inc., PulmoGeniX™ Technologies, Inc., and GastroGeniX™, Inc.
Graduating from medical school at age 21, Dr. Mehindru was one of the youngest graduates in his country of birth, India. At age 27, he served on the faculty of the Cleveland Clinic where he was a top-tier internal medicine resident and did research in gastroenterology. Vinay has a second residency from the University of Florida in emergency medicine.
Vinay joined a private group of emergency physicians on the east coast of Florida with 47 providers, 75 employees, and over 100,000 annual visits. He has tremendous experience in airway management; working at a level-two trauma center for 10 years. For 16 years, he had been an instructor teaching difficult airway management for both cardiovascular life support and pediatric advanced life support.
At the University of Texas at Dallas, he received an Executive MBA with honors, earning the Beta Gamma Sigma Award offered only to the world’s top 5% of business students. Dr. Mehindru is the Founder & CEO of Exemplary Health, a fully integrated health plan for self-funded employers built on the principles of population health management. With AdventHealth he has been a Chief Medical Officer and was President of AdventHealth’s Physician Network, Tampa Bay, a population health company. As President of AdventHealth’s clinically integrated networks, Dr. Mehindru built a network of 1,000 physicians and established quality benchmarks and metrics. He successfully reduced the annual historical increase in the cost of their employee health plan. As a voting member of AdventHealth West Florida Division Strategy and Growth council, Dr. Mehindru oversaw strategic initiatives of this $1.5 billion revenue division.
Dr. Mehindru said, “I am excited to be on the board of RetinalGenix. This technology is designed to screen large populations at relatively lower costs and reduce the overall disease burden in the given population. It addresses all 3 components of the triple aim of population health management from the Institute for Healthcare Improvement (IHI): 1. Improve the health of the population 2. Reduce per capita cost 3. Improve the experience by improving the access.”
“We welcome Dr. Mehindru joining the RetinalGenix Technologies, Inc. Board of Directors. His MBA, Public health, and medical health background should complement numerous RetinalGenix initiatives including the Company’s initiatives to improve population health management and planned upgrade from OTCQB to list on NASDAQ,” said RetinalGenix’s chairman and CEO Jerry Katzman, MD.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding the appointment of Dr. Mehindru supporting the Company’s initiatives to improve population health management and planned listing upgrade from OTCBQB to NASDAQ and the Company’s technology screening large populations at relatively lower costs and reducing the overall disease burden in the given population. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the contribution of Dr. Mehindru to the Company, the ability of the Company’s technology to screen large populations at relatively lower costs and reduce the overall disease burden in the given population and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contact: RetinalGenix Technologies, Inc. Jerry Katzman, CEO jkatzman@retinalgenix.com www.retinalgenix.com
